1. Home
  2. SNAL vs VERU Comparison

SNAL vs VERU Comparison

Compare SNAL & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Snail Inc.

SNAL

Snail Inc.

N/A

Current Price

$0.81

Market Cap

40.1M

Sector

Technology

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

N/A

Current Price

$4.33

Market Cap

40.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNAL
VERU
Founded
2000
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.1M
40.9M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
SNAL
VERU
Price
$0.81
$4.33
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
10.8M
63.1K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
120.00
N/A
EPS
N/A
N/A
Revenue
$81,225,622.00
$16,296,958.00
Revenue This Year
$15.53
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.36
52 Week High
$2.16
$4.59

Technical Indicators

Market Signals
Indicator
SNAL
VERU
Relative Strength Index (RSI) 48.54 89.88
Support Level $0.62 $2.16
Resistance Level $0.98 N/A
Average True Range (ATR) 0.15 0.48
MACD -0.03 0.17
Stochastic Oscillator 7.40 50.64

Price Performance

Historical Comparison
SNAL
VERU

About SNAL Snail Inc.

Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: